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(57) ABSTRACT 
System and method for enclosing cells andor tissue, for 
purposes of growth, cell differentiation, suppression of cell 
differentiation, biological processing andor transplantation 
of cells and tissues (biological inserts), and for secretion, 
sensing and monitoring of selected chemical substancesand 
activation of gene expression of biological inserts implanted 
into a human body. Selected cells andlor tissue are envel- 
oped in a “cage” that is primarily carbon nanotube Bucky 
paper, with a selected thickness and porosity. Optionally, 
selected functional groups, proteins andor peptides are 
attached to the carbon nanotube cage, or included within the 
cage, to enhance the growth andlor differentiation of the 
cells andor tissue, to select for certain cellular sub-popula- 
tions, to optimize certain functions of the cells andor tissue 
andor to optimize the passage of chemicals across the cage 
surface(s). A cage system is also used as an immuns shield 
and to control operation of a nano-device or macroscopic 
device, located within the cage, to provide or transform a 
selected chemical andor a selected signal. 
42 Claims, 4 Drawing Sheets 
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PROVISION OF CARBON NANOTUBE 
BUCKY PAPER CAGES FOR IMMUNE 
SHIELDING OF CELLS, TISSUES, AND 
MEDICAL DEVICES 
STATEMENT REGARDING FEDERALLY 
SPONSORED REASEACH AND 
DEVELOPMENT 
most biological applications for efficient transfer of nutrients 
and other biological factors into the interior of the cage, and 
efficient transfer of waste products, metabolites and secreted 
substances from inside the cage to outside the cage. 
What is needed is a biocompatible material that can be 
formed into a “cage” or similar structure for containing cells 
or tissue that prevents or limits access by the host immune 
system to the foreign cells or tissue. The cage material 
should allow the cells and/or tissue to be maintained in a live 
This invention was made by an employee of the federal 10 and functioning state; and in some cases, should permit the 
government The U.S. Government has rights in this appli- cells and/or tissue to carry out normal (physiological) and 
cation. specially engineered sensing functions and/or normal 
(physiological) or specially engineered secretory functions. 
The cage material itself should not provoke (or should limit 
15 significantly) an immune response in the host system. The 
cage material itself should not elicit (or should limit signifi- 
cantly) scar formation in the host that, together with an 
immune response, could lead to obstruction of the pores of 
the cage material. The cage material itself should resist 
20 protein deposition that, together with scar formation or an 
immune response, could lead to obstruction of the pores. 
Preferably, the material should be flexible and sufficiently 
resilient to withstand the forces that may be involved in 
surgical implantation or transplantation and other forces that 
25 may be present in the host environment. The material should 
be configurable into a variety of geometric shapes, to 
optimize transport of substances across the cage and to 
5 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
(Not Applicable) 
INCORPORATION BY REFERENCE OF 
MATERIAL SUBMITTED ON A COMPACT 
DISK 
(Not Applicable) 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
This invention relates to fabrication and use of carbon 
nanotube Bucky paper “cages” for immune shielding of cells 
and tissues, for transplantation and other activities. 
promote the maintenance of cells and/or tissues. 
30 BRIEF SUMMARY OF THE INVENTION 
2. Description of the Related Art 
Transplantation of cells and tissues from one human to These needs are met by the invention, which provides 
another is limited by the host immune system, which iden- construction of one or more cages, envelopes, enclosures or 
tifies and rejects non-host cells and tissues with high effi- receptacles (referred to collectively herein as a “cage”), 
ciency. One strategy for avoiding or surmounting this barrier 35 made primarily of carbon nanotube Bucky paper 
is to enclose the cells in a “cage” that provides a biological (“CNTBP”) that have a selected degree of porosity, or 
shield (an “immune shield”) that, it is hoped, will prevent the “leakiness,” to accept and hold tissues, cells and/or mixtures 
transplanted cells and tissues from being rejected by the host of cells (collectively referred to herein as a “biological 
immune system. This strategy would have application in insert”), for the purpose of maintaining the cells and/or 
endocrinology (e.g., islet cell transplantation), gene therapy 40 tissue in a live state, for the purpose of growth or processing 
(transplantation of cells to provide a missing protein or to of the cells and/or tissue and/or for the purpose of trans- 
replace a dysfunctional protein), immune therapy, or other plantation of the cells and/or tissue from one region of the 
biological therapy (transplantation of cells to provide spe- body to another region of the body within the same organ- 
cific immunoglobulins, cytokines, immune regulators or ism, and/or for the purpose of transplantation of cells and/or 
biological response modifiers). Such a system could also 45 tissue from a donor organism to a recipient organism, even 
provide a micro-environment, within a human or other host when the donor organism and the recipient organism are 
body, for tissue engineering, to allow for differentiation of different species or are unrelated immunologically. 
cells or assembly of tissue structures with two-dimensional The CNTBP cage supports a strategy of transplanting into 
or three-dimensional architecture or the formation of nascent a recipient host multiple types of cells andor tissue, which 
organs, for subsequent use in the host or elsewhere. 50 need not be immune compatible with the host, in various 
Immune shielding may also serve as an important strategy environments and for various applications. The invention 
for preventing immune rejection of implantable medical can also provide an immune-shielded microenvironment, 
devices that range in size from ultra-small scale nanopar- within a human or other host body, in which temperature, 
ticles and nanoprobes to large scale macroscopic devices. pH, oxygen levels, carbon dioxide levels, nutrient levels, 
The strategy of immune shielding allows use of a wider 55 metabolite levels, and levels of cytokines and other regula- 
range of materials in the construction of implantable medical tory molecules (including molecules that may not be char- 
devices than would otherwise be possible because of the acterized) are optimum. This approach will promote or 
presence of the host immune system. support a variety of useful biological processes that may be 
Many materials have been proposed as immune shields, difficult or impossible when cells and/or tissue are main- 
including specially treated biological and non-biological 60 tained in culture outside the body. These processes could 
materials, silicon, ceramics, synthetic polymers and other include maintenance of cells and/or tissue in a live state, 
non-organic materials. As a rule, these foreign materials tend differentiation of cells and/or tissue, de-differentiation of 
to provoke an immune response in the host body, and this cells and/or tissue, enrichment of certain cell types from 
has limited development in this field. Another phenomenon mixtures of cells and/or tissue, and removal of certain cell 
associated with transplantation of foreign materials into a 65 types from mixtures of cells and/or tissue. Other processes 
host is localized scar formation and/or obstruction of pores could include formation of two-dimensional or three-dimen- 
in the foreign material. The presence of pores is required in sional tissue structures from cells or mixtures of cells, 
US 7,070,923 B1 
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including formation of nascent organs. The invention also 
makes possible the inclusion of scaffold structures, template 
structures, beads, and other structures or objects that can be 
placed inside a CNTBP cage (but made of materials that 
need not be biocompatible with the human or host body), 
which can be used to enhance the desired biological pro- 
cesses, including formation of two-dimensional and three- 
dimensional structures. 
In some cases, the maintenance of cells and/or tissue in 
the cage or other biological processes may require that 
certain growth factors, hormones, cytokines and/or extra- 
cellular matrix proteins also be included in the cage. In onler 
to prevent these growth factors, hormones, cytokines and/or 
extra-cellular matrix proteins from leaking out of the porous 
cage, it may be necessary (or desirable) to attach these 
growth factors, hormones, cytokines, andor extra-cellular 
matrix proteins to beads, particles or other objects to be 
included in the cage, where the bead or particle size prevents 
these molecules from passing through the pores of the cage. 
The cage material can be chemically modified by strate- 
gies such as: surface adsorption of various substances; 
covalent coupling; addition of hydrogen, oxygen, nitrogen, 
sulfur, halides and other chemical groups; cross-linking of 
materials to cause entanglement with the CNTBP; or other 
methods, to suit the particular application, to make the 
resulting CNTBP cage more suitable for a particular host 
type, to make the CNTBP cage more suitable for a specific 
location or environment within a host body, to help retain the 
CNTBP cage in a specified location within the host body, to 
select or enhance certain biological functions or processes of 
the cell and/or tissue contained within the CNTBP cage, 
and/or to avoid or minimize the need for use of immuno- 
suppressive drugs by the host. 
In some cases, modifications of the cage material may be 
more appropriately carried out before construction of the 
cage. In other cases, modification of the cage, after its basic 
structure is formed, may be more appropriate, to allow 
specific modifications to be present only on the outside of 
the cage or only on the inside of the cage. In addition to cells 
or tissues, structures such as beads or other objects can be 
included within the cage, either attached to an inside wall of 
the cage or “free-floating,” in order to enhance selected 
biological processes within the cage. 
An immune-shield cage may also be configured to pro- 
vide sensing, monitoring and/or secretion functions, for 
example, by controlling the porosity or another relevant 
parameter to permit passage of selected atoms and mol- 
ecules across the cage walls. 
BRIEF DESCRIPTION OF SEVERAL VIEWS OF 
THE DRAWINGS 
FIGS. lA,  lB, 1C and 1D illustrate construction of a 
single layer or multi-layer cylindrical or toroidal cage for 
practice of an embodiment of the invention. 
FIGS. 2A and 2B illustrate construction of a multi-sheet 
cage for practice of another embodiment of the invention. 
FIG. 3 illustrates a multi-cage system, according to the 
invention, for control of secretion rate of an active biological 
substance ABS. 
FIG. 4 illustrates use of a cage system, according to the 
invention, to monitor for the presence of, or concentration 
of, a target substance. 
FIG. 5 is a scanning electron microphotograph (SEM) 
image of a piece of CNTBP. 
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DETAILED DESCRIPTION OF THE 
INVENTION 
The invention uses carbon nanotube Bucky paper 
(“CNTBP’)), a mesh of carbon nanotubes (CNTs), single- 
walled or multi-walled, whose thickness, density and/or 
porosity can be controlled in a manufacturing process. 
CNTBP is made entirely of carbon and is biocompatible and 
capable of supporting growth of some biological cells and/or 
tissues. 
When properly prepared, a CNTBP cage will serve as a 
substrate for cell and/or tissue growth, and as a container for 
such cells (including cells, artificial cells, platelets, lipo- 
somes, proteoliposomes or other lipid-membrane-delimited 
structures) and/or tissue (including groups of cells, aggre- 
gates of cells, two-dimensional and three-dimensional 
assemblies of cells, tissue fragments, organ fragments, arti- 
ficially assembled nascent organs and extra-cellular matrix 
elements). 
Additionally, the CNTBP cage will serve as a barrier for 
selectively preventing invasion of unwanted biological cells 
and/or tissue, such as immune effector cells and blood 
vessels. Because it is a mesh of CNTs, CNTBP is porous and 
will allow oxygen, carbon dioxide, glucose, amino acids, 
peptides, some proteins and other molecules to diffuse 
relatively easily through the CNT mesh, even through mul- 
tiple layers of CNT mesh. For many applications, antibodies 
may be permitted to cross the cage material. Because 
attachment of antibodies to cells, by itself, is not detrimental 
to the cells, if T-lymphocytes, macrophages, neutrophils or 
other immune effector cells cannot gain access to the anti- 
body-coated cells 
For some applications, however, such as for use of the 
CNTBP cage to shield tissue, immune effector cells, such as 
T-lymphocytes, macrophages and neutrophils may already 
be present in the tissue. This situation may make it necessary 
to prevent antibodies from entering the CNTBP cage, or may 
make it necessary to inactivate the antibodies that enter the 
cage, or make it necessary to inactivate or inhibit the 
immune effector cells, in order to preserve the health of the 
CNTBP-shielded tissue. 
FIGS. lA,  1B and 1C illustrate construction of a multi- 
layer cylindrical cage according to an embodiment of the 
invention. Two or more sheets of CNTBP 11-i (i=l, . . . , I) 
are aligned with each other in FIG. 1A and are rolled 
together to form a cylinder 13, with inner diameter d l  and 
outer diameter d2, as shown in FIG. 1B. The substance to be 
transplanted, processed or grown within the cylinder con- 
sisting of cells and/or tissue, including but not limited to 
cells, mixtures of cells, tissue, fragments of tissue, glands, 
fragments of glands, organs and fragments of organs) is 
positioned between the sheets 11-i shown in FIG. 1A and/or 
is positioned between the sheets and within the cylinder 
interior shown in FIG. 1B. 
In FIG. lC,  one or both ends, 15E1 and 15E2, of the 
cylinder 13 are sutured or otherwise stitched together to 
form a liquid-tight or molecule-tight end structure. Prefer- 
ably, the exposed sides, 17-s-i of the rolled-up sheets are 
also sutured or stitched together to provide a liquid-tight or 
molecule-tight region for an active biological substance 
ABS at and adjacent to the sutures. With the ends, 15E1 and 
15E2, of the cylinder 13 stitched together, the (side) walls of 
the resulting structure control ingress of atoms and mol- 
ecules into, and egress from, the cylinder interior, including 
egress of an active biological substance, A B S  to the ambient 
medium. 
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In FIG. lD, the two ends, 15E1 and 15E2, of the (former) The rate at which the active biological substance ABS is 
cylinder 13 are joined together by sutures so that the secreted into the patent’s body is determined by the intrinsic 
resulting structure is a torus 19. This toroidal structure has sensing function of the cells andor tissue (e.g., for insulin 
at least two advantages relative to the cylindrical structure secreting cells and/or tissue, sensing of the presence of 
13 in FIG. 1C: (1) only one set (rather than two sets) of 5 glucose) and is not limited by the CNTBP cage, if the 
sutures is required to join or otherwise close the (former) CNTBP cage can be made sufficiently porous. 
cylinder ends; and (2) all surface regions on the torus 19 in In some cases, it may be possible to use the CNTBP cage 
FIG. 1D will react in approximately the same manner with as a delivery system to provide release of an ABS into a body 
the ambient medium (including, but not limited to, blood, by placing the ABS directly into the CNTBP cage (Le., 
plasma and lymph fluid) surrounding part or all of the torus, 10 without using cells andor tissue to secrete the ABS). Where 
whereas the surface regions of the sutured ends, 15E1 and an active biological substance ABS is passively released 
15E2, of the cylinder 13 in FIG. 1C may react somewhat from a cage, one concern is the inevitable decrease in rate of 
differently than the remainder of the cylinder surface release as the concentration of the active biological sub- 
regions. stance ABS within the cage decreases. This decrease in rate 
In an alternative approach, adjacent CNTBP sheets, 11-i 15 can be controlled, although not eliminated, by enclosing a 
and 11-(i+l), are pressed together, but not tightly, so that second pocket or pouch 32 of the active biological substance 
adjacent layers of the cylinder 13 or torus 19 have a small ABS, with a second initial ABS concentration c2(t=O), 
volume of a liquid or gas, including the cells andor tissue within a first, larger pocket or pouch 31 of the active 
between them. The equivalent porosity of the cylinder or biological substance, having an initial ABS concentration 
torus walls may be higher than in the first alternative so that 20 cl(t=O), which is in turn immersed in an ambient medium 
a more diverse group of atoms and molecules is permitted AM, having a relatively unvarying ABS concentration 
ingress into, and egress from, the cylinder or torus interior. cO(t=O), as illustrated in FIG. 3. Preferably, the concentra- 
The equivalent porosity, leakage rate andor substances that tion values satisfy cO(t=O)~<cl(t=O)<<c2(t=O). The rate 
are permitted to leak are determined, in part, by the indi- constants for diffusion of the active biological substance 
vidual CNTBP sheet thicknesses, the density of the CNTs 25 ABS from the first pocket to the second pocket, and from the 
used, the number of layers presented by the rolled-up sheets second pocket to the first pocket, have the respective values 
11-i, and the average separation distance (measured in k,, and k,,, where these two values may be equal or 
microns) between adjacent sheets of the rolled-up cylinder unequal. The rate constants for diffusion of the active 
sheets. This second alternative is useful where the substance biological substance ABS from the first pocket to the ambi- 
in the interior of the cylinder 13 or torus 19 is used for 30 ent-medium AM, and from the ambient medium to the first 
monitoring of, or for secretion to, an environment outside pocket, have the respective values k,, and k,, where these 
the cylinder. two values may be equal or unequal. Preferably, k,,&,,. 
FIGS. 2A and 2B illustrate construction of a multi-sheet The cage material for the first pocket should be CNTBP or 
cage according to another embodiment of the invention. Two another material that serves as an immune shield; the cage 
or more sheets of CNTBP 214 (i=1, . . . , J) are aligned with 35 material for the second pocket may be an immune shield 
each other in FIG. 2A, and the cells andor tissue are material or another suitable material. This arrangement is 
positioned between the sheets. In FIG. 2B, the sheets are analyzed in an Appendix. By suitable choices of ratios of the 
sutured or otherwise stitched together to form a sheet parameters, the rate of decrease of the resulting secretion 
assembly 23 so that the cells and/or tissue cannot leak from rate k,,.cl(t) from the first pocket or pouch to the ambient 
within the sheet assembly at or adjacent to the suture region. 40 medium Ah4 is reduced relative to the rate of decrease that 
Optionally, a central region of the sheets assembly 23 is would occur if the first pouch, but not the second pouch, is 
sutured to form a pocket or pouch 25, defined by sutures 27 present. The rate of decrease of the resulting passive release, 
that holds most or all of the cells andor tissue. A pocket may k,,.cl(t), from the first pocket or pouch to the ambient 
be formed by creating one or more dimples in a sheet of medium AM may be further reduced by provision of N 
CNTBP. 45 pockets, numbered n=l, . . . , N (N23), with pocket number 
Where the CNTBP cage is used for growth, differentia- n being larger than and enclosing pocket number n+l 
tion, non-differentiation or transplantation of cells andor (n=l, . . . , N-1). This approach may be used for a CNTBP 
tissue, the cage porosity may be selected to allow passage of cage or for a first cage made of any other material that serves 
some molecules and to exclude passage of other molecules. as an immune shield. A stand-alone first pocket 31 can also 
Where the CNTBP cage is used for such processing of cells 50 be used for secretion, if the decrease in passive release rate 
andor tissue, the cage walls preferably have a selected for the active biological substance ABS from the pocket is 
porosity that permits exchange of one or more selected not a great concern. 
molecules between the cage interior and the cage exterior, A CNTBP cage may also be used to sense the presence or 
such as 0,, CO,, amino acids, glucose, peptides and small monitor the concentration of one or more selected target 
proteins. 55 substances TS in an ambient medium AM surrounding part 
The CNTBP cage may also be used for secretion of one or all of the cage 41, as illustrated in FIG. 4. In this situation, 
or more active biological substances ABS at one or more the CNTBP material is modified, as appropriate, to allow or 
controlled rates, from the cage interior to the cage exterior. promote transfer of the target substance across the cage 
As an example, where the patient has a non-functioning or material, from the ambient medium AM to the cage interior. 
poorly functioning pancreas or thyroid, a substitute tissue, 60 A chemical substance or device 42, which reacts and under- 
organ fragments or cells from another human, or even from goes a chemical or physical reaction, is located within the 
another species, may be enclosed in a cage, acting as an cage interior. The presence or intensity of this resulting 
immune shield, within the patient’s body. The cage protects reaction within the cage is monitored to determine the 
the non-self cells andor tissue from an immune reaction by presence or the concentration of the target substance TS in 
the patient’s body but allows secretion of the desired active 65 the ambient medium AM. 
biological substance ABS (e.g., insulin or thyroid hormone) A CNTBP cage can also support implantation into a host 
into the patent’s body adjacent to the location of the cage. body of a biological insert that is genetically engineered to 
US 7,070,923 B1 
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possess a specialized function. The activity associated with of these functional groups may serve as “markers” in a 
this function is controlled by an agent that can regulate manner similar to biological markers on a cell membrane, 
specific gene expression or other specific biological activity thereby selectively controlling the chemical substances that 
in the biological insert and thus provide the specialized are transferred across a cage wall and/or the rate at which 
function. For some applications, the biological insert is 5 such transfer occurs. 
implanted with the specialized function turned off (inactive). CNTBP Preparation. In one approach, the CNTBP used in 
This insert is maintained in the host body in a live state until the invention is prepared from crude preparations of single 
the specialized function is needed, at which point the bio- wall carbon nanotubes (“SWCNTs”) synthesized by a laser 
logical insert is activated, for example, by administration of ablation technique, available from commercial sources. 
a chemical or biological triggering agent. When the special- 10 Other preparations of SWCNTs or multiple wall carbon 
ized function is no longer needed, a second triggering agent nanotubes (“MWCNTs”), such as those synthesized by the 
is adhinistered to deactivate the insert or expression of the well known HiPC0 technique (a high pressure process using 
specific gene or specific biological activity of the insert. carbon monoxide) are also acceptable. The crude prepara- 
Alternatively, a third triggering agent can be administered to tion is first purified by refluxing in nitric acid for 160 hours 
trigger death or its equivalent in the biological insert. This 15 and the resulting product is centrifuged. A pellet (resulting 
approach may have particular usefulness in providing medi- from centrifugation) is suspended in potassium hydroxide 
cal care to military personnel or to astronauts on long space solution (pH=lO), then washed twice by centrifugation and 
flights, where access to conventional medical care is limited. re-suspension. The purified CNTs are washed twice in 
A CNTBP cage, acting as a quasi-immune shield, can also distilled water, using centrifugation and resuspension. The 
enclose a mechanical, electromechanical, electronic or 20 purified CNTs are re-suspended in distilled water, then 
physical medical device, which functions best when pro- mechanically formed into Bucky paper by removal of water 
tected from exposure to or contact with one or more selected by vacuum filtration over a cellulose filter or similar filter. 
molecular substances. The medical device may provide or Portions of the CNTs incorporated in the Bucky paper 
transform a selected chemical or a selected chemical signal, produced here may be “bundled”, or partially or fully 
optical signal, electronic signal, electromagnetic signal, 25 aligned, due to liquid flow through the mesh of CNTs, which 
ultrasound signal, mechanical signal or other signal within may provide a higher than normal density of CNTs in an 
the cage, for subsequent use inside or outside the cage, and array. 
may be a nano-device (with a device diameter of the order The CNTBP used in the invention preferably has a 
of nanometers to microns) or may be a larger device, thickness in the range of 1-100 pm and an area density in the 
referred to here as a macroscopic device. The CNTBP cage 30 range of 420-1500 pgmlcm2. FIG. 5 is a scanning electron 
material may prevent passage of selected molecular sub- microphotograph (SEM) image of a Bucky paper scrap after 
stance(s) and may permit passage of other selected molecu- fabrication. 
lar substances, but does not interfere directly with operation Separate procedures are optionally provided for generat- 
of the medical device. One or more selected chemical, ing and controlling patterns or densities of growth of an 
optical, electronic, electromagnetic, ultrasound or mechani- 35 array of SWCNTs or MWNTs, with a CNT length that 
cal signals can be generated externally and passed through depends upon the structure involved. A CNT can be grown 
the CNTBP cage material to activate, deactivate, control or with a length between about 1 Fm and 200 pm, or longer if 
otherwise change the status of the medical device within the desired. However, control of the length of the CNTs may not 
cage. Apart from replacement of mis-functioning or non- be important for CNTBP applications. The CNTBP support 
functioning medical devices and their respective cages from 40 material will preferably form a mesh or mat. The mesh 
time to time, no further actions are required, other than thickness h(mesh) and mesh density partly determine the 
passage of the selected signal, or sequence of signals, CNTBP porosity. A mesh density range of 4 ~ 1 0 ~ - 6 ~ 1 0 ’ ~  
through the cage material. cm2, corresponding to a range d=40 MI-5 pm for average 
Activation of the biological insert can be implemented, nearest neighbor center-to-center separation distance is pro- 
for example, using one or more optical or other suitable 45 duced where a substrate is not used for CNT growth. Use of 
signals to “awaken” the specialized function of the insert. a higher Bucky paper average thickness h may require use 
The optical signal may have one or more wavelengths in the of a higher separation distance d, to preserve similar Bucky 
visible, infrared or microwave regions, depending upon the paper behavior. 
distance of the CNTBP cage from an exposed portion of the Unique features of this invention include a material 
host body through which the optical signal enters. A timed 50 (CNTBP) that has not yet been used extensively in biologi- 
sequence of non-simultaneous optical signals can be used to cal applications, the biocompatibility of the material, the 
raise the energy level of a particular electron or group of potential to permit or block the passage of various sub- 
electrons to a selected level(s) at which activation occurs. An stances across the CNTBP by controlling the porosity of the 
ultraviolet optical signal can be used for such purpose, if the CNTBP, the ease of use and variety of shapes into which the 
CNTBP cage is located close to an exposed surface of the 55 material can be shaped, and an ability to control the dimen- 
body, for example, in a skin layer. Until such activation sions of a cage made from the material. The invention 
occurs, the biological insert within the CNTBP cage is provides a micro-environment in which growth, promotion 
effectively inert. Delivery of one or more selected optical of or suppression of cell differentiation, transplantation of 
signals can also be used to deactivate an already-active cells and tissues, as well as secretion, sensing and monitor- 
biological insert so that the biological insert can be switched 60 ing of chemical substances present can be performed, with- 
on and off, depending upon need. out the need for, or with limited need for, use of immuno- 
Transfer characteristics across a meshwork of CNTBP suppressive drugs or other special precautions. 
material can also be modified by inclusion and/or attachment 
of selected functional groups (e.g.. groups involving H, 0, 
N, S, F, C1, Br, I, a protein, a peptide, a polypeptide, a growth 65 
factor, a cytokine, a nucleic acid and/or a nucleic acid 
polymer) to the CNTs before the CNTBP is prepared. Some 
Appendix 
In the structure shown in FIG. 3, a first envelope 31 is 
immersed in an ambient medium AM, referred to with the 
US 7,070,923 B1 
9 10 
index “0,” having an initial concentration cO(t=O) of a 
selected active biological substance (ABS) The first enve- 
lope 31 is constructed of carbon nanotube Bucky paper 
(CNTBP) and contains the ABS with an initial concentration 
of c l (c0) .  A second envelope 32, constructed of CNTBP or 5 
another selected material, is wholly contained within the 
first envelope 31 and contains the ABS with an initial 
concentration of c2(t=O). Transfer of the A B S  from between 
the second envelope and the region R12 within the first 
envelope that is outside the second envelope, and between 10 
the region R12 and the ambient medium AM are approxi- 
mately described by the equations 
What is claimed is: 
1. A system for enclosing a biological tissues or group of 
cells for positioning within an ambient medium, the system 
comprising: 
a cage or envelope of a cage material that includes 
primarily carbon nanotube Bucky paper (“CNTBF‘”), 
the cage having at least one of a cage thickness in a 
range 1-100 pm and a cage area density in a range of 
420-1500 pgm/cm2, where the cage encloses at least 
one of a biological tissue or a group of cells (referred 
to herein as a “biological insert”) and an interior pf the 
cage is substantially isolated from an ambient medium 
surrounding the cage, except for transport at least one 
species of molecule between the cage interior and the 
2. The system of claim 1, wherein said cage is used to 
(Cl.Vl), (A-2) grow said biological insert without provoking a substantial 
where co, c l  and c2 are concentrations (in Units of mm-3) Of to 
the ABS in the ambient medium, in the region R12 and in the 20 place cells derived from a cell culture into a biological host 
second envelope interior, respectively, k n  and k12 are dif- without provoking a substantial immunological response 
fusion rate constants for transfer of the ABS from the second from the biological host. 
envelope interior to the region R12 and from the region R12 4. ne system of claim 1, wherein said cage is used to 
to the second envelope interiorl 161 and k10 are diffusion rate place at least one of a bacterial cell, a yeast cell, a mam- 
constants for transfer of the ABS from the ambient medium 25 malian cell and a non-mammalian cell into a biological host 
to the region R12 and from the region R12 to the ambient without provoking a substantial i m u n o ~ o g i c ~  response 
medium, vo is the ambient medium volume, v1 is the from the biological host. 
volume of the region R12, V2 is the volume of the second 5. ne system of claim 1, wherein said biological insert 
envelope interior, S10 is the surface area of the first envelope includes at least one of cell differentiation 
is the surface area of the second envelope. Introducing the cell without provoking a immuno~ogic. 
parameters response from said ambient medium. 
6. The system of claim 1, wherein said cage is modified 
by addition of an active biological substance to said interior 
7. The system of claim 6, wherein said active biological 
substance is selected to be at least one of a protein, a peptide, 
a polypeptide, a growth factor, a cytokine, a nucleic acid and 
a nucleic acid polymer. 
8. The system of claim 6, wherein said active biological 
substance is added to said cage interior by at least one of: 
non-specific adsorption, covalent coupling and chemical 
cross-linking so that said active biological substance 
becomes entangled with said CNTBP cage material. 
9. The system of claim 6, wherein said active biological 
substance is added to said cage interior by attachment to a 
bead so that the bead and said attached active biological 
substance cannot be transported from inside said cage to 
It is asshmed here that cO(t=O)<<cl(t=O)<<c2(t=O). 10. The system of claim 6, wherein said cage interior, 
Several observations can be made from Eqs. 64-41 and modified by said addition of said active biological substance 
(A-5). First, the magnitude of the exponential decrease with enhances at least one process of: growth, differentiation, 
time Of the concentration variable d ( t )  is less than the &-differentiation, assembly into a two-dimensional cell 
magnitude of the exponential decrease of that variable that 55 structure, and assembly into a three-dimensional cell struc- 
would occur if the second envelope were absent. Second, the ture, of said biological insert. 
Concentration variable Cl(t) decreases toward a Smaller 
Positive value. the surface area SI2 is an important by at least one of covalent attachment of an active biological 
parameter in moderating the magnitude of the exponential substance to an exterior of said cage and adsorption of the 
decrease of the concentration variable cl(t). With the second 6o active biological substance to the exterior of said cage. 
envelope present, the decrease in the net exchange rate of the 12. ne system of claim 11, wherein said active biologic. 
ABS, substance is selected to be at least one of a protein, a peptide, 
a polypeptide, a growth factor, a cytokine, anucleic acid and 
a nucleic acid polymer. 
across the first envelope surface is reduced, and the 65 13. The system of claim 11, wherein said cage exterior, 
exchange rate is maintained at a value closer to a constant modified by said addition of said active biological substance 
value. enhances immune shielding by said cage. 
d(~l~Vl)/dt=-{(kl~~Sl~)/Vl+(k,,.S,,)IV1)(~l~Vl)+ 
{ (kzl .Sizt lv2}(~2.v2){(~i.S~o)/VO}(~O.VO), 
d(~2.v2)/dt=-{(kzl.S,,)IV2)(c2-V2)+{(k,’.Sl~)/V1 } 
(A-1) 
15 ambient medium. 
immunological response from said ambient medium. 
3. ne system of claim 1, wherein said cage is 
that is 
(between the ambient medium and the region R12), and s12 30 and said cage promotes cell differentiation by the at least one 
CHkZl.SIdlV2,  
P=(klZ~SIZ)Ivl, 35 of said cage. 
x=(ko~~S,o)~vo, 
&@io SioYK 
K={ -@[P2+k]”’}/2(<0), 
(A-3) 
40 
the physically realistic and interesting solution of the 
coupled equations (A-1) and (A-2) becomes 
xc(O).VO/(aZ-a.ga)}exp(at), 
Cl(t).Vl={ d ( ~ 2  v2)/dt+(r4t).V2}/@, 
45 
c2(t).v2= { C2(0).v2-XC(O).VO/(a2-a@a)}eXp(Kt)+ 
(A-4) 
(A-5) 
5o outside said cage. 
11. The system of claim 1, wherein said cage is modified 
(kio.SioYV1 }(cl.V1)-(koi.Sio)/VO)(cO.M), 
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14. The system of claim 1, wherein said biological insert 
includes at least one cell that is capable of cell differentiation 
and said cage suppresses cell differentiation by the at least 
one cell without provoking a substantial immunological 
response from a biological host that contains said cage. 
15. The system of claim 1, wherein said cage is used to 
transplant said biological insert from a first organism to a 
second organism without provoking a substantial immuno- 
logical response from at least one of the first organism and 
the second organism. 
16. The system of claim 1, wherein said cage is used to 
,transplant said biological insert from a first region of a host 
body to a second region of the host body without provoking 
a substantial immunological response from the host body. 
17. The system of claim 1, wherein said cage has at least 
two adjacent layers of said CNTBP material and substan- 
tially has a shape drawn from a class of cage shapes 
consisting of a cylinder, a torus and a multiple-sheet stmc- 
ture. 
18. The system of claim 1, wherein said cage is chemi- 
cally modified by addition of at least one of a hydride, a 
nitride, an oxide, a halide, a sulfide, a protein, and a peptide 
to said cage material. 
19. A system for providing secretion of an active biologi- 
cal substance into an ambient medium, the system compris- 
an active biological substance enclosed in a cage or 
envelope of a cage material that includes primarily 
carbon nanotube Bucky paper (“CNTBP”), having at 
least one of a cage thickness in a range 1-100 pm and 
a cage area density in a range of 420-1500 pg/cm2, 
where an interior of the cage is substantially isolated 
from an ambient medium located in an exterior of the 
cage, except for transport of molecules of at least one 
species between the cage interior and the cage exterior, 
and where the active biological substance has a positive 
rate of transfer across the cage material from the cage 
interior to the cage exterior. 
20. The system of claim 19, wherein said cage further 
encloses at least one of a thyroid tissue or portion of a 
thyroid gland and said cage permits transfer of a thyroid 
hormone or other composition that includes iodine from 
inside said cage to outside said cage. 
21. The system of claim 19, wherein said cage further 
encloses at least one of a pancreas tissue or portion of a 
pancreas gland and said cage permits transfer of a pancreas 
hormone or other composition that includes insulin from 
inside said cage to outside said cage. 
22. The system of claim 19, wherein said cage is chemi- 
cally modified by addition of at least one of a protein, a 
peptide and a molecule including at least one of a hydrogen 
atom, an oxygen atom, a nitrogen atom, a sulfur atom, a 
fluorine atom, a chlorine atom, a bromine atom and an iodine 
atom to said cage material. 
23. A method for providing secretion of an active bio- 
logical substance into an ambient medium, the method 
comprising: 
enclosing at least one of a tissue and a group of cells 
(referred to herein as a “biological insert”), having a 
capability of secreting a chemical and having an insert 
first concentration, in a first cage or envelope of a first 
cage material that includes primarily carbon nanotube 
Bucky paper (“CNTBP), having at least one of a cage 
thickness in a range 1-100 ym and a cage area density 
in a range of 420-1500 pgdcm2, where the biological 
ing: 
12 
insert has a positive rate of transfer across the first cage 
material from a first cage interior to a first cage exterior; 
and 
enclosing a second biological insert, having an insert 
second concentration, in a second cage or envelope of 
a second cage material, having a second cage thickness, 
where an interior of the second cage is contained within 
the first cage and where the second biological insert 
within the second cage has a positive rate of transfer 
across the second cage material from a second cage 
interior to the first cage interior. 
24. The method of claim 23, further comprising enclosing 
within said second cage at least one of a thyroid tissue and 
a portion of a thyroid gland. 
25. The method of claim 23, further comprising enclosing 
within said second cage at least one of a pancreas tissue and 
a portion of a pancreas gland. 
26. The method of claim 23, further comprising chemi- 
cally modifying said cage by addition of at least one of a 
20 protein, a peptide and a molecule including at least one of a 
hydrogen atom an oxygen atom, a nitrogen atom, a sulfur 
atom, a fluorine atom, a chlorine atom, a bromine atom and 
an iodine atom to said cage material. 
27. A method for monitoring at least one of presence and 
25 concentration of an active biological substance in an ambi- 
enclosing a monitoring substance, which reacts with a 
monitored substance and undergoes at least one of a 
chemical change and a physical change, in a cage or 
envelope of a cage material that includes primarily 
carbon nanotube Bucky paper (“CNTBP”), the cage 
having at least one of a cage thickness in a range 1-100 
pm and a cage area density in a range of 420-1500 
pgdcm’, where an interior of the cage is substantially 
isolated from an ambient medium located in an exterior 
of the cage and where the monitored substance has a 
positive rate of transfer across the cage material 
between a cage exterior and a cage interior; and 
when the monitoring substance undergoes at least one of 
the chemical change and the physical change, the 
system interprets this condition to indicate that the 
monitored substance is present in the ambient medium. 
28. The method of claim 27, further comprising chemi- 
cally modifying said cage by addition of at least one of a 
45 protein, a peptide and a molecule including at least one of a 
hydrogen atom, an oxygen atom, a nitrogen atom, a sulfur 
atom, a fluorine atom, a chlorine atom, a bromine atom and 
an iodine atom to said cage material. 
29. A method for controlling activity of a biological tissue 
enclosing a biological tissue or group of cells (referred to 
herein as a “biological insert”) that is initially in an 
inactive state, in a cage or envelope of a cage material 
that includes primarily carbon nanotube Bucky paper 
(“CNTBP”), the cage having at least one of a cage 
thickness in a range 1-100 ym and a cage area density 
in a range of 420-1500 pgdcm’, where an interior of 
the cage is substantially isolated from an ambient 
medium located in an exterior of the cage; and 
at a first time, administering a triggering agent to at least 
one of the ambient medium and the cage interior to 
activate the biological insert and to permit at least part 
of the activated biological insert to secrete an active 
biological substance within the cage. 
30. The method of claim 29, further comprising admin- 
istering, at a second time subsequent to said first time, a 
second triggering agent to at least one of said ambient 
5 
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medium and said cage interior to deactivate said activated 
biological insert that is located in at least one of said cage 
interior and said ambient medium. 
31. The method of claim 29, further comprising chemi- 
cally modifying said cage by addition of at least one of a 
protein, a peptide and a molecule including at least one of a 
hydrogen atom, an oxygen atom, a nitrogen atom, a sulfur 
atom, a fluorine atom, a chlorine atom, a bromine atom and 
an iodine atom to said cage material. 
32. A method for providing a medical device within a host 
body, the method comprising: 
enclosing a medical device in a cage or envelope of a cage 
material that includes primarily carbon nanotube 
Bucky paper ("CNTBP"), having at least one of a cage 
thickness in a range 1-100 pm and a cage area density 
in a range of 420-1500 pgm/cm2, where an interior of 
the cage is substantially isolated from an ambient 
medium surrounding the cage, except for transport of a 
molecule of at least one species between the cage 
interior and the ambient medium where the cage mate- 
rial acts as a shield to prevent molecules, other than the 
at least one species molecule, in the ambient medium 
from contacting the device; 
when the medical device is initially inactive, providing a 
medical device activation signal that activates the 
device at an activation time; and 
when the medical device is initially active, providing a 
medical device inactivation signal that inactivates the 
device at an inactivation time. 
33. The method of claim 32, further comprising selecting 
said medical device to be a nano-device that provides or 
transforms at least one of a chemical and a signal within said 
cage. 
34. The method of claim 32, further comprising selecting 
said medical device to be a macroscopic device that provides 
or transforms at least one of a chemical and a signal within 
said cage. 
35. The method of claim 32, further comprising providing 
at least one of said activation signal and said inactivation 
signal as at least one of a chemical signal, an optical signal, 
an electronic signal, an electromagnetic signal, an ultra- 
sound signal and a mechanical signal that is initially pro- 
duced outside said cage, passes through said cage material, 
and interacts with said medical device. 
5 36. The method of claim 32, further comprising: 
when said medical device is initially active, providing a 
medical device control signal that changes at least one 
operating parameter for said medical device at a control 
time. 
37. The method of claim 36, further comprising providing 
at least one of said activation signal and said inactivation 
signal as at least one of a chemical signal, an optical signal, 
an electronic signal, an electromagnetic signal, an ultra- 
sound signal and a mechanical signal that is initially pro- 
1s duced outside said cage, passes through said cage material, 
and interacts with said medical device. 
38. The system of claim 6,  wherein said active biological 
substance is produced by said biological insert within said 
cage. 
39. The system of claim 38, wherein said active biological 
substance enhances at least one of the following processes 
associated with said biological insert: growth, differentia- 
tion, de-differentiation, assembly into a two-dimensional 
cell structure, and assembly into a three-dimensional cell 
40. The system of claim 1, wherein said cage is modified 
by at least one of covalent attachment an active biological 
substance to an exterior of said cage and adsorption of the 
active biological substance to the interior of said cage. 
41. The system of claim 1, wherein said biological insert 
includes at least one cell that is capable of cell differentiation 
and said cage promotes cell differentiation by the at least one 
cell without provoking a substantial immunological 
response from a biological host that contains said cage. 
42. The method of claim 29, further comprising choosing 
said active biological substance from the group of sub- 
stances consisting of insulin, cytokines and biological 
response modifiers. 
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